Table 2. Analysis for early and late recurrence-free survival using the univariate and multivariate Cox proportional hazards regression model in the training cohort.
| Variables | Early recurrence-free survival | Late recurrence-free survival | ||||||
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
| Age | 0.985 (0.969-1.001) | 0.072 | 1.010 (0.994-1.027) | 0.229 | ||||
| Gender (F/M) | 0.503 (0.253-1.002) | 0.051 | 0.766 (0.441-1.331) | 0.345 | ||||
| HBsAg (+/-) | 1.432 (0.719-2.852) | 0.307 | 1.219 (0.665-2.234) | 0.522 | ||||
| HBV DNA (>105/103-105/0) | 1.323 (1.023-1.712) | 0.033 | 1.222 (0.939-1.591) | 0.136 | 1.109 (0.860-1.430) | 0.425 | ||
| HCV infection (+/-) | 1.609 (0.296-6.537) | 0.506 | 0.895 (0.125-6.424) | 0.912 | ||||
| Cirrhosis (+/-) | 0.816 (0.537-1.240) | 0.341 | 1.413 (0.916-2.181) | 0.118 | ||||
| Portal hypertension (+/-) | 0.971 (0.529-1.783) | 0.924 | 1.519 (0.909-2.540) | 0.111 | ||||
| Ascites (+/-) | 2.004 (1.160-3.461) | 0.013 | 1.865 (1.086-3.202) | 0.024 | 1.559 (0.868-2.800) | 0.137 | ||
| AFP (≥400/<400) | 1.969 (1.301-2.982) | 0.001 | 1.735 (1.127-2.669) | 0.012 | 1.438 (0.955-2.166) | 0.082 | ||
| Tumor size (≥5/<5) | 2.259 (1.438-3.547) | <0.001 | 1.688 (1.048-2.717) | 0.031 | 1.255 (0.837-1.883) | 0.271 | ||
| Tumor number (multiple/single) | 1.594 (0.960-2.646) | 0.071 | 1.757 (1.051-2.937) | 0.032 | 1.167 (0.270-5.045) | 0.836 | ||
| Differentiation (Poor /Well-Moderate) | 0.926 (0.607-1.412) | 0.721 | 1.084 (0.718-1.636) | 0.703 | ||||
| Macrovascular invasion | 2.627 (1.212-5.692) | 0.014 | 1.034 (0.412-2.597) | 0.943 | N/A | N/A | ||
| Microvascular invasion | 2.240 (1.480-3.389) | <0.001 | 1.648 (1.043-2.604) | 0.032 | 1.692 (1.104-2.592) | 0.016 | 1.571 (1.014-2.435) | 0.043 |
| BCLC (B-C/0-A) | 1.673 (1.041-2.688) | 0.033 | 1.221 (0.696-2.144) | 0.486 | 1.762 (1.075-2.888) | 0.025 | 1.377 (0.334-5.676) | 0.658 |
| TNM (III-IV/I-II) | 1.271 (0.801-2.015) | 0.309 | 1.465 (0.927-2.316) | 0.102 | ||||
| TLS (+/-) | 0.485 (0.295-0.797) | 0.004 | 0.501 (0.302-0.830) | 0.007 | 0.804 (0.521-1.241) | 0.326 | ||
F: female; M: male; HBV: hepatitis B virus; HCV: hepatitis V virus; AFP: alpha-fetoprotein; BCLC: Barcelona Clinic of Liver Cancer; TNM: tumor-nodes-metastasis; TLS: tertiary lymphoid structures; HR, hazard ratio; CI, confidence interval; N/A: not available (cases were too little).